Fan, Rong <br/><br/>
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.  [electronic resource] 

 -  Gut  Feb 2016 
 - 313-20 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-3288 
<br/><br/><label>Standard No.: </label>10.1136/gutjnl-2014-308546  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Cohort Studies<br/>Female<br/>Hepatitis B Antibodies--analysis<br/>Hepatitis B e Antigens--immunology<br/>Hepatitis B, Chronic--immunology<br/>Humans<br/>Interferon-alpha--therapeutic use<br/>Male<br/>Nucleosides--therapeutic use<br/>Polyethylene Glycols--therapeutic use<br/>Recombinant Proteins--therapeutic use<br/>Retrospective Studies<br/>Sensitivity and Specificity<br/>Seroconversion